The combination of Semax and Selank is one of the most discussed pairings in peptide and nootropic research. Both peptides were developed in Russia and are often seen as complementary compounds due to their impact on different areas of brain function. Semax is primarily studied for its effects on cognitive function, memory, neuroprotection, and neuroplasticity, while Selank is analyzed mainly in the context of anxiety regulation, stress resilience, emotional balance, and GABAergic signaling [1–8].
Due to these differences, researchers are considering whether combining Semax and Selank may offer broader neurological support than using each peptide individually. While the biological rationale for such an approach seems compelling, direct clinical studies on the simultaneous use of both peptides remain limited.
What do Semax and Selank do?
Although both peptides interact with the central nervous system, they appear to act through different biological pathways.
Semax is a synthetic peptide derived from ACTH(4-10). Studies suggest that it may affect learning processes, memory, attention, neuroprotection, and recovery from neurological damage. Experimental studies have shown that Semax can modulate dopamine and serotonin activity, increase brain-derived neurotrophic factor (BDNF) levels, regulate TrkB receptor activity, and influence genes related to inflammation, immune response, and neuronal survival [9–15].
Selank, on the other hand, is a synthetic analog of tuftsin, investigated primarily for its anxiolytic and emotion-regulating properties. Research findings suggest it may act as a positive allosteric modulator of GABA receptors, inhibit enzymes responsible for enkephalin breakdown, influence BDNF expression, and regulate neurotransmitter systems involved in stress response and mood control [1–5]. Clinical studies have observed anxiolytic effects comparable to some conventional anxiolytics with minimal sedative effects [6].
Can Semax and Selank be combined?
One of the most frequently asked questions is about the possibility of using Semax and Selank simultaneously.
From a biological perspective, such a combination seems interesting, as both peptides affect different but complementary systems in the brain. Semax is primarily associated with supporting cognitive functions, neuroplasticity, and neuroprotection, while Selank is more related to stress regulation, emotional stability, and anxiety reduction [1–15].
Since their mechanisms of action do not appear to directly overlap, many researchers consider them complementary peptides rather than redundant.
However, it should be emphasized that no large clinical trials directly evaluating the combination of Semax and Selank have been published to date. Most discussions regarding this stack are based on the analysis of biological mechanisms, clinical observations, and user reports, rather than direct comparative studies.
Potential Benefits of Semax and Selank Stack
The potential benefits of combining Semax and Selank are related to their different areas of biological activity.
Research on Semax indicates potential support for attention, memory formation, learning ability, mental performance, neuroplasticity, and neuroprotection. Numerous studies have demonstrated increased BDNF expression and activation of pathways associated with neuronal survival and synaptic adaptation [10–15].
Research on Selank primarily focuses on anxiety reduction, emotional regulation, stress resilience, GABA signaling, and neuroimmunomodulation. Its effects on enkephalin metabolism, BDNF regulation, and neurotransmitter systems related to emotional stability and mood have also been demonstrated [1–6].
Due to these differences, Semax and Selank are often discussed as potential solutions to simultaneously support cognitive performance and emotional well-being.
Semax and Selank Cognitive Functions and Concentration
One reason for interest in this combination is the fact that anxiety and chronic stress can negatively affect cognitive abilities. Semax has been studied for its potential to support learning, memory, and mental performance, while Selank has been investigated in the context of reducing anxiety and improving emotional balance [1-15].
Theoretically, simultaneously supporting cognitive functions and stress regulation can create more favorable conditions for concentration, productivity, and mental efficiency. It is this potential complementary effect that makes the combination of both peptides often discussed in the nootropics and peptides communities.
Semax, Selank, and Neuroplasticity
Both peptides are linked to neurotrophic signaling pathways, particularly those involving BDNF.
Experimental studies have shown that Semax can increase the expression of BDNF and TrkB receptors in brain areas responsible for learning and memory [10,11]. Separate studies have also shown that nasal administration of Selank can affect BDNF expression in the hippocampus [7].
Since BDNF plays a key role in neuroplasticity, neuronal adaptation, learning processes, and memory formation, some researchers believe that the combined effect of Semax and Selank on these pathways may contribute to their nootropic potential. However, it should be emphasized that direct studies analyzing the impact of the combination of both peptides on neuroplasticity are still limited.
Is stacking Semax and Selank better than either peptide individually?
Currently, there is no clear scientific evidence indicating that the combination of Semax and Selank is more effective than using either peptide separately.
For studies focusing primarily on memory, attention, learning, neuroprotection, or neurological regeneration, Semax currently has a stronger scientific basis. On the other hand, for studies concerning anxiety, emotional regulation, stress resistance, and GABA system-related mechanisms, Selank has gathered a larger amount of data [1–15].
The basis for interest in this combination is the possibility of simultaneously supporting cognitive and emotional processes. However, further clinical trials with human subjects are needed before drawing definitive conclusions.
What to Choose: Semax, Selank, or Both Peptides?
The answer depends primarily on the research objective.
If the main area of interest is cognitive functions, memory, concentration, learning, or neuroprotection, Semax is the peptide most studied for these applications. If, however, the goal of research is anxiety reduction, emotional balance, stress adaptation, or regulation of the GABAergic system, Selank is typically the preferred research peptide.
Researchers interested in both cognitive performance and emotional resilience often analyze the possibility of combining both peptides, as they appear to influence different neurobiological systems [1–15].
Instead of competing with each other, Semax and Selank are often seen as complementary peptides that affect different aspects of brain function.
Summary
The Semax and Selank stack combines two of the most recognizable neuroactive peptides developed in Russia. Semax is primarily studied for cognitive function, neuroprotection, memory, and neuroplasticity, while Selank is analyzed mainly in the context of anxiety reduction, stress resilience, and emotional regulation.
Current research suggests that both peptides interact with different biological pathways and may provide complementary effects. However, direct clinical studies on the simultaneous use of Semax and Selank are still limited, and therefore further human studies are needed to determine if such a combination offers an advantage over the use of each peptide separately.
Disclaimer
This article is for educational and informational purposes only. Semax and Selank are research peptides, and scientific knowledge regarding their mechanisms of action and long-term effects is constantly evolving. The information presented is a summary of findings from published laboratory, preclinical, and clinical studies and should not be interpreted as medical advice, therapeutic recommendation, or confirmation of efficacy.
For research purposes only: The Semax and Selank products offered by Semax Polska are intended solely for laboratory and scientific research. They are not approved for human consumption or for use for medical, diagnostic, therapeutic, or preventive purposes. All research materials should be used in accordance with applicable laws and the guidelines of institutions conducting scientific research.
References
[1] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[3] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[4] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on Anxiety-Phobic States and Body Weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804
[5] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[6] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[7] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[8] Monis, A., & Maple, K. (2024). Sermorelin medical evidence. White Paper Review of Growth Hormone-Releasing Peptide Mechanisms and Neuroregulatory Pathways.
[9] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotonergic Brain Systems in Rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[10] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax Regulates BDNF and TrkB Expression in the Rat Hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[11] Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Y. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax Binds Specifically and Increases BDNF Protein Levels in Rat Basal Forebrain. Journal of Neurochemistry, 97(Suppl. 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
[12] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborskaia, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). The Peptide Semax Affects Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia. BMC Genomics, 15, 228. https://doi.org/10.1186/1471-2164-15-228
[13] Medvedeva, E. V., Dmitrieva, V. G., Limborskaya, S. A., Myasoedov, N. F., & Dergunova, L. V. (2017). Semax Regulates Expression of Immune Response Genes During Ischemic Brain Injury in Rats. Molecular Genetics and Genomics, 292(3), 635–653. https://doi.org/10.1007/s00438-017-1297-1
[14] Sudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborskaia, S. A., & Dergunova, L. V. (2021). Brain Protein Expression Profile Confirms the Protective Effect of Semax in Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[15] Gusev, E. I., Martynov, M. Y., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The Efficacy of Semax in Patients at Different Stages of Ischemic Stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68